Status:
TERMINATED
Prognostic Value of CTC in HNSCC Patients
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Recurrence
Metastasis
Eligibility:
All Genders
20+ years
Brief Summary
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
Detailed Description
1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) 2. Disease status: locally advanced or recurrent/metastasized at initial presentation 3. Age \>=20 years ol...
Eligibility Criteria
Inclusion
- histologically or cytopathologically proven head and neck squamous cell carcinoma Age ≥ 20 years. Measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.
- Ability to sign informed consent.
Exclusion
- Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers.
- Inability to comply with study and/or follow-up procedures.
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01884129
Start Date
June 1 2012
End Date
May 1 2015
Last Update
December 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 333